Skip to content

Intratympanic injection combined with systemic glucocorticoids in the treatment of unilateral sudden deafness hearing prognosis prediction model: a retrospective observational study

Intratympanic injection combined with systemic glucocorticoids in the treatment of unilateral sudden deafness hearing prognosis prediction model: a retrospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061379
Enrollment
Unknown
Registered
2022-06-22
Start date
2022-06-22
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden hearing loss

Interventions

Treatment effective group:Intratympanic injection combined with systemic corticosteroids
Treatment ineffective group:Intratympanic injection combined with systemic corticosteroids

Sponsors

The Second Affiliated Hospital of PLA Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1) Age 18~84 years old 2) Patients with unilateral sudden deafness greater than 30 dB occurring on at least three consecutive frequencies for unknown reasons within 72 hours

Exclusion criteria

Exclusion criteria: 1) Middle ear lesions, retrocochlear mass, Meniere's disease, and large vestibular aqueduct syndrome; 2) Genetic factors and other pathogenic factors; 3) Pregnant women and those with contraindications to glucocorticoid use; 4) Medical records Incomplete information.

Design outcomes

Primary

MeasureTime frame
pure tone hearing threshold;

Secondary

MeasureTime frame
White blood cell count;age;BMI;Hypertension;Triglyceride;Total Cholesterol;High Density Lipoprotein-Cholesterol;Low Density Lipoprotein-Cholesterol;Fasting Plasma Glucose;Absolute Neutrophil Count;Lymphocyte count;neutrophil to lymphocyte ratio(NLR);monocyte;red blood cell count;platelet count(PLT);platelet to lymphocyte ratio(PLR);activated partial thromboplastin time(APTT);fibrinogen dissolution products(FDP);fibrinogen(Fib);incentive;location;tinnitus;Aural fullness;vertigo;course;

Countries

China

Contacts

Public ContactLian-Jun Lu
lulianj@fmmu.edu.cn+86 13991239935

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026